optum© de-identified clinformatics® data mart (Optum Inc)
90
Structured Review
Optum Inc
optum© de-identified clinformatics® data mart
Optum© De Identified Clinformatics® Data Mart, supplied by Optum Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/optum%C2%A9+clinformatics%C2%AE+data+mart/de+identified+clinformatics+data+mart+database/pmc10785894-1-1-0
Average 90 stars, based on 1 article reviews
Optum© De Identified Clinformatics® Data Mart, supplied by Optum Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/optum%C2%A9+clinformatics%C2%AE+data+mart/de+identified+clinformatics+data+mart+database/pmc10785894-1-1-0
Average 90 stars, based on 1 article reviews
optum© de-identified clinformatics® data mart - by Bioz Stars,
2026-09
90/100 stars
Images
1) Product Images from "Comparative Merits of Available Mortality Data Sources for Clinical Research"
Article Title: Comparative Merits of Available Mortality Data Sources for Clinical Research
Journal: AMIA Annual Symposium Proceedings
doi:
Figure Legend Snippet: Commonly used commercially available real-world data sources
Techniques Used:
Related Articles
Medications:Article Title: Patterns of glucocorticoid prescribing and provider-level variation in a commercially insured incident rheumatoid arthritis population: a retrospective cohort study Article Snippet: This retrospective cohort study used Article Title: Fracture Risk After Initiating Canagliflozin: A Multi-Database Cohort Study Article Snippet: We conducted a population-based, new-user, longitudinal-cohort study using two commercial insurance claims databases in the United States (US): de-identified Article Title: Abstracts of the 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Pennsylvania Convention Center, Philadelphia, PA, USA, August 24-28, 2019. Article Snippet: Methods: Both designs drew eligible patients from the Truven Health MarketScan Commercial database, the Article Title: Changes in Erythropoiesis Stimulating Agent Use Under a Risk Evaluation and Mitigation Strategy (REMS) Program. Article Snippet: Introduction Risk evaluation and mitigation strategy (REMS) programs are intended to improve safe use of US Food and Drug Administration-approved drugs.. However, controversy exists over whether they consistently accomplish this goal.. Objective We aimed to assess how initiation of the erythropoiesis stimulating agents (ESAs) darbepoetin alfa and epoetin alfa changed following implementation and enforcement (following a 1-year post-implementation grace period) of a prominent REMS program warning physicians against use in cancer patients with hemoglobin above 10 g/dL. Article Title: Special Issue: Abstracts of the 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Virtual, September 16-17, 2020. Article Snippet: Methods: Using real world data from the Article Title: Special Issue: Abstracts of the 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Virtual, September 16-17, 2020. Article Snippet: Methods: We utilized Article Title: Risk of Incident Type 2 Diabetes Mellitus Among Patients With Rheumatoid Arthritis: A Population-Based Cohort Study. Article Snippet: This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record.. Please cite this article as doi: 10.1002/ACR.24343 This article is protected by copyright.. All rights reserved MS. YINZHU JIN (Orcid ID : 0000-0002-1397-3106) DR. SEOYOUNG C KIM (Orcid ID : 0000-0002-2517-3579) Article type : Original Article Risk of incident type 2 diabetes among patients with rheumatoid arthritis: a population-based cohort study Yinzhu Jin, MS, MPH1, Sarah K. Chen, MD, MPH1,2, Jun Liu, MD, MPH1, Seoyoung C. Kim, MD, ScD, MSCE1,2 1 Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 2 Division of Rheumatology, Inflammation and Immunity, Brigham and Women’s Hospital, Boston, MA; Harvard Medical School, Boston, MA. Article Title: Risk of Serious Infection in Patients Receiving Systemic Medications for the Treatment of Psoriasis Article Snippet: Overall Serious Infections in Patients With Psoriasis and Psoriatic Arthritis on Systemic Medications Compared With Infection:Article Title: Patterns of glucocorticoid prescribing and provider-level variation in a commercially insured incident rheumatoid arthritis population: a retrospective cohort study Article Snippet: This retrospective cohort study used Article Title: Fracture Risk After Initiating Canagliflozin: A Multi-Database Cohort Study Article Snippet: We conducted a population-based, new-user, longitudinal-cohort study using two commercial insurance claims databases in the United States (US): de-identified Article Title: Abstracts of the 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Pennsylvania Convention Center, Philadelphia, PA, USA, August 24-28, 2019. Article Snippet: Methods: Both designs drew eligible patients from the Truven Health MarketScan Commercial database, the Article Title: Changes in Erythropoiesis Stimulating Agent Use Under a Risk Evaluation and Mitigation Strategy (REMS) Program. Article Snippet: Introduction Risk evaluation and mitigation strategy (REMS) programs are intended to improve safe use of US Food and Drug Administration-approved drugs.. However, controversy exists over whether they consistently accomplish this goal.. Objective We aimed to assess how initiation of the erythropoiesis stimulating agents (ESAs) darbepoetin alfa and epoetin alfa changed following implementation and enforcement (following a 1-year post-implementation grace period) of a prominent REMS program warning physicians against use in cancer patients with hemoglobin above 10 g/dL. Article Title: Special Issue: Abstracts of the 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Virtual, September 16-17, 2020. Article Snippet: Methods: Using real world data from the Article Title: Special Issue: Abstracts of the 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Virtual, September 16-17, 2020. Article Snippet: Methods: We utilized Article Title: Risk of Incident Type 2 Diabetes Mellitus Among Patients With Rheumatoid Arthritis: A Population-Based Cohort Study. Article Snippet: This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record.. Please cite this article as doi: 10.1002/ACR.24343 This article is protected by copyright.. All rights reserved MS. YINZHU JIN (Orcid ID : 0000-0002-1397-3106) DR. SEOYOUNG C KIM (Orcid ID : 0000-0002-2517-3579) Article type : Original Article Risk of incident type 2 diabetes among patients with rheumatoid arthritis: a population-based cohort study Yinzhu Jin, MS, MPH1, Sarah K. Chen, MD, MPH1,2, Jun Liu, MD, MPH1, Seoyoung C. Kim, MD, ScD, MSCE1,2 1 Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 2 Division of Rheumatology, Inflammation and Immunity, Brigham and Women’s Hospital, Boston, MA; Harvard Medical School, Boston, MA. Article Title: Risk of Serious Infection in Patients Receiving Systemic Medications for the Treatment of Psoriasis Article Snippet: Overall Serious Infections in Patients With Psoriasis and Psoriatic Arthritis on Systemic Medications Compared With |